At the same time, it is lowering the price of the 2.5mg vial from its launch price of $399 to $349 per month and the 5mg dose from $549 to $499.

The drug has been approved for the treatment of acute myocardial infarction (AMI) by the FDA since 2000, and – while Roche doesn't separate Activase and TNKase sales in its financial reporting ...

Eli Lilly, the manufacturer of Zepbound, made Zepbound available on its online pharmacy, LillyDirect, in August 2024. The medication is available as a single-dose vial or an auto-injector pen.